Skip to main content
Industry News
Rolling submission initiated for CAR T-cell therapy
1/12/2021

Janssen and Legend Biotech have begun a rolling submission of a biologics license application for ciltacabtagene autoleucel, or cilta-cel, their chimeric antigen receptor T-cell therapy candidate. The partners are seeking approval as a treatment for adults with relapsed or refractory multiple myeloma.

Full Story: